Vistagen enrolls first subject in fasedienol repeat dose study for social anxiety disorder

Vistagen Therapeutics, Inc.

Phase 2 exploratory trial evaluating repeat dose of fasedienol (3.2 mcg) in adults with SAD during a public speaking challenge.
Three arms: fasedienol+fasedienol (total 6.4 mcg), fasedienol+placebo (3.2 mcg), placebo+placebo; second dose 10 min after initial.
Study design mirrors ongoing PALISADE Phase 3 program including open-label extension.
CEO notes no FDA-approved acute treatment option exists for SAD despite high prevalence.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.